Christopher Del Corral
Overview
Explore the profile of Christopher Del Corral including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al.
N Engl J Med
. 2021 Dec;
386(7):629-639.
PMID: 34904798
Background: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy...
2.
Awasthi R, Pacaud L, Waldron E, Tam C, Jager U, Borchmann P, et al.
Blood Adv
. 2020 Feb;
4(3):560-572.
PMID: 32045475
The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated...
3.
Bishop M, Maziarz R, Waller E, Jager U, Westin J, McGuirk J, et al.
Blood Adv
. 2019 Jul;
3(14):2230-2236.
PMID: 31332046
Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies...
4.
Chiu A, Shumaker K, Del Corral C, George B, Kasper M, Elie-Turenne M, et al.
Am J Emerg Med
. 2017 Nov;
36(2):339.
PMID: 29108799
No abstract available.
5.
Chiu A, Shumaker K, Del Corral C, George B, Kasper M, Jois P, et al.
Am J Emerg Med
. 2017 Feb;
35(8):1147-1149.
PMID: 28236513
We report a case series of three low to intermediate risk chest pain patients who presented to the emergency department and were managed as outpatients via the Cellular Outpatient Twelve-Lead...